This global biochemical profiling technology, called mVision, will provide analysis of samples from bioreactors. Using mVision, Pfizer will be able to rapidly understand cellular metabolism in the biopharmaceutical production process, which in turn will enable Pfizer to optimize bioprocesses and to reduce manufacture costs.
The use of metabolomics for bioprocess optimization is said to be a novel application for the latest of the ‘omics’ technologies.
John Ryals, president and CEO of Metabolon, said: “Pfizer’s commitment to our platform demonstrates the power of metabolomics for understanding complex systems like bioreactors. By monitoring a large number of biochemicals in a bioreactor process, customers can quickly uncover areas for optimization.”